|
Age (years)a
|
57.48 (±24.01)
|
61.53 (±22.44)
|
44.56 (±24.99)
|
0.013
|
0.98 (0.96–1.04)
|
0.494
|
|
Body weight (kg)a
|
73.67 (±21.33)
|
72.78 (±18.90)
|
76.50 (±28.26)
|
0.547
|
-
|
-
|
|
Male genderb
|
45 (67.2%)
|
33(76.1%)
|
12 (75.0%)
|
0.55
|
-
|
-
|
|
Charlson Co-morbidity Scorea
|
2.88 (±2.39)
|
2.86 (±2.14)
|
2.94 (±3.15)
|
0.914
|
-
|
-
|
|
Diabetes mellitusb
|
29 (43.2%)
|
25 (49.0%)
|
4 (25.0%)
|
0.15
|
0.52 (0.06–4.87)
|
0.568
|
|
Baseline CrCl (mL/min)a
|
133.60 (±92.54)
|
126.02 (±85.57)
|
157.94 (±111.52)
|
0.23
|
0.99 (0.98–4.87)
|
0.108
|
|
Baseline serum albumin (mg/L)a
|
28.65 (±4.45)
|
27.86 (±4.19)
|
31.19 (±4.48)
|
0.008
|
0.72 (0.57–0.93)
|
0.010
|
|
Intensive care unit careb
|
21 (31.3%)
|
13 (25.5%)
|
8 (50.0%)
|
0.12
|
16.38 (1.37–195.55)
|
0.027
|
|
Receipt of CMS Loading dose
|
52 (77.6%)
|
39 (76.5%)
|
13 (81.3%)
|
1.0
|
-
|
-
|
|
CMS Dose (mU/kg/day)a
|
0.11 (±0.04)
|
0.11 (±0.04)
|
0.10 (±0.04)
|
0.48
|
-
|
-
|
|
Cumulative CMS dose (mU)a
|
101.21 (±47.37)
|
106.47 (±45.91
|
84.44 (±49.56)
|
0.105
|
1.00 (1.00–1.00)
|
0.133
|
|
Duration of CMS therapy (days)a
|
13.76 (±6.77)
|
14.16 (±5.54)
|
12.50 (±9.86)
|
0.397
|
0.96 (0.83–1.11)
|
0.555
|
|
Number of concomitant nephrotoxic agentsa
|
0.71 (±0.62)
|
0.76 (±0.65)
|
0.56 (±0.51)
|
0.26
|
2.37 (0.50–11.19)
|
0.277
|
|
Concomitant vancomycin therapyb
|
33 (49.3%)
|
24 (47.1%)
|
9 (56.3%)
|
0.576
|
-
|
-
|
|
Concomitant furosemide therapyb
|
11 (16.4%)
|
8 (15.7%)
|
3 (18.75%)
|
0.715
|
-
|
-
|
|
Concomitant aminoglycoside therapyb
|
3 (4.47%)
|
2 (3.92%)
|
1 (6.25%)
|
0.559
|
-
|
-
|
|
Concomitant NSAIDb
|
2 (2.98%)
|
2 (3.92%)
|
0 (0.0%)
|
1.00
|
-
|
-
|
|
Concomitant radiological contrastb
|
1 (1.49%)
|
1 (1.96%)
|
0 (0.0%)
|
1.00
|
-
|
-
|
|
Concomitant amphotericin b therapyb
|
0 (0.0%)
|
0 (0.0%)
|
0 (0.0%)
|
1.00
|
-
|
-
|
